
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom's stock outlook remains positive due to a notable increase in international revenue, which grew 22% year-over-year, indicating successful market penetration and recent coverage wins in key regions such as France and Canada. The company's domestic business also showed significant growth, achieving approximately $852 million in revenue, a 21% increase, driven by a strong influx of new customers from the Type 2 diabetes segment. Furthermore, DexCom raised its full-year sales guidance, now anticipating revenues between $4.630 billion and $4.650 billion, bolstered by long-term trends in remote monitoring, innovative pipeline developments, and a more accessible business model.
Bears say
DexCom is adjusting its profitability outlook downward, signaling potential challenges ahead as it anticipates a gross margin reduction to 61% due to rising scrap issues. The company failed to achieve a record number of new patients in Q3, a concerning trend that may reflect ongoing quality issues impacting business performance as competition intensifies. Additionally, a notable decrease in adjusted EBIT and EBITDA projections further highlights financial uncertainties, with forecasted year-over-year growth rates for 2026 and 2027 now lowered to approximately 12% and 13%, indicating a cautious outlook in a competitive market.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares